Literature DB >> 23619939

Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine.

Jan Booij, Javier Arbizu, Jacques Darcourt, Swen Hesse, Flavio Nobili, Pierre Payoux, Sabina Pappatà, Klaus Tatsch, Zuzana Walker, Marco Pagani.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 23619939     DOI: 10.1007/s00259-013-2415-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  37 in total

1.  Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.

Authors:  N M Kemppainen; S Aalto; I A Wilson; K Någren; S Helin; A Brück; V Oikonen; M Kailajärvi; M Scheinin; M Viitanen; R Parkkola; J O Rinne
Journal:  Neurology       Date:  2006-09-13       Impact factor: 9.910

2.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

3.  Imaging amyloid deposition in Lewy body diseases.

Authors:  S N Gomperts; D M Rentz; E Moran; J A Becker; J J Locascio; W E Klunk; C A Mathis; D R Elmaleh; T Shoup; A J Fischman; B T Hyman; J H Growdon; K A Johnson
Journal:  Neurology       Date:  2008-09-16       Impact factor: 9.910

4.  EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2.

Authors:  Koen Van Laere; Andrea Varrone; Jan Booij; Thierry Vander Borght; Flavio Nobili; Ozlem L Kapucu; Zuzana Walker; Kjell Någren; Klaus Tatsch; Jacques Darcourt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236

5.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

Authors:  Henryk Barthel; Hermann-Josef Gertz; Stefan Dresel; Oliver Peters; Peter Bartenstein; Katharina Buerger; Florian Hiemeyer; Sabine M Wittemer-Rump; John Seibyl; Cornelia Reininger; Osama Sabri
Journal:  Lancet Neurol       Date:  2011-04-08       Impact factor: 44.182

6.  Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

Authors:  Nelleke Tolboom; Maqsood Yaqub; Ronald Boellaard; Gert Luurtsema; Albert D Windhorst; Philip Scheltens; Adriaan A Lammertsma; Bart N M van Berckel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-22       Impact factor: 9.236

7.  Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging.

Authors:  Michel Koole; Dewi M Lewis; Christopher Buckley; Natalie Nelissen; Mathieu Vandenbulcke; David J Brooks; Rik Vandenberghe; Koen Van Laere
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

8.  Alzheimer disease: Aβ-independent processes-rethinking preclinical AD.

Authors:  Gaël Chételat
Journal:  Nat Rev Neurol       Date:  2013-02-12       Impact factor: 42.937

9.  Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.

Authors:  Adam S Fleisher; Kewei Chen; Yakeel T Quiroz; Laura J Jakimovich; Madelyn Gutierrez Gomez; Carolyn M Langois; Jessica B S Langbaum; Napatkamon Ayutyanont; Auttawut Roontiva; Pradeep Thiyyagura; Wendy Lee; Hua Mo; Liliana Lopez; Sonia Moreno; Natalia Acosta-Baena; Margarita Giraldo; Gloria Garcia; Rebecca A Reiman; Matthew J Huentelman; Kenneth S Kosik; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  Lancet Neurol       Date:  2012-11-06       Impact factor: 44.182

10.  A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.

Authors:  Agneta Nordberg; Stephen F Carter; Juha Rinne; Alexander Drzezga; David J Brooks; Rik Vandenberghe; Daniela Perani; Anton Forsberg; Bengt Långström; Noora Scheinin; Mira Karrasch; Kjell Någren; Timo Grimmer; Isabelle Miederer; Paul Edison; Aren Okello; Koen Van Laere; Natalie Nelissen; Mathieu Vandenbulcke; Valentina Garibotto; Ove Almkvist; Elke Kalbe; Rainer Hinz; Karl Herholz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-08       Impact factor: 9.236

View more
  6 in total

1.  Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice.

Authors:  Ugo Paolo Guerra; Flavio Mariano Nobili; Alessandro Padovani; Daniela Perani; Alberto Pupi; Sandro Sorbi; Marco Trabucchi
Journal:  Neurol Sci       Date:  2015-06       Impact factor: 3.307

2.  Amyloid imaging in atypical dementia.

Authors:  Robert Laforce; Gil D Rabinovici
Journal:  CMAJ       Date:  2014-01-20       Impact factor: 8.262

3.  Quantification of 18F-florbetapir PET: comparison of two analysis methods.

Authors:  Chloe Hutton; Jerome Declerck; Mark A Mintun; Michael J Pontecorvo; Michael D Devous; Abhinay D Joshi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-05       Impact factor: 9.236

4.  Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.

Authors:  Solveig Tiepolt; Swen Hesse; Marianne Patt; Julia Luthardt; Matthias L Schroeter; Karl-Titus Hoffmann; David Weise; Hermann-Josef Gertz; Osama Sabri; Henryk Barthel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-30       Impact factor: 9.236

5.  Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria.

Authors:  Eva María Triviño-Ibáñez; Raquel Sánchez-Vañó; Pablo Sopena-Novales; Juan Carlos Romero-Fábrega; Antonio Rodríguez-Fernández; Cristóbal Carnero Pardo; María Dolores Martínez Lozano; Manuel Gómez-Río
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

6.  Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo.

Authors:  L Saint-Aubert; F Nemmi; P Péran; E J Barbeau; P Payoux; F Chollet; J Pariente
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.